Daptomycin(dap toe mye’ sin)
Cubicin
PREGNANCY CATEGORY B
Drug Classes
Cyclic lipopeptide antibiotic
Therapeutic Actions
Binds to bacterial cell membranes, causing a rapid depolarization of membrane potential. The loss of membrane potential leads to the inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death.
Indications
-
Treatment of complicated skin and skin-structure infections caused by susceptible strains of the following gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, and Enterococcus faecalis (vancomycin-susceptible strains only)
-
Treatment of S. aureus bloodstream infections, including right-sided endocarditis caused by methicillin-susceptible and methicillin-resistant S. aureus
-
Unlabeled use: Treatment of vancomycin-resistant Enterococcus faecium
Contraindications and Cautions
-
Contraindicated with known allergy to daptomycin.
-
Use cautiously with pregnancy, lactation, renal impairment.
Available Forms
Powder for injection—500 mg/vial
Dosages
Adults
-
Skin and skin-structure infections: 4 mg/kg IV given over 30 min or as an IV injection over 2 min in 0.9% sodium chloride injection every 24 hr for 7–14 days.
-
Bacteremia: 6 mg/kg/day IV over 30 min or as an IV injection over 2 min for 2–6 wk or longer.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
For patients with CrCl less than 30 mL/min or for those on dialysis, give 4 mg/kg IV once every 48 hr (6 mg/kg for S. aureus bloodstream infections).
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
